Brief Summary
The investigators hypothesize that the combination of eribulin and zanzalintinib will be tolerable and lead to improved progression-free survival (PFS) as compared to eribulin alone based on historical data.
Protocol Interventions
Drug: Zanzalintinib, Drug: Eribulin